Abstract
With the advent of highly active antiretroviral therapy, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is becoming a more chronic, manageable disease; nevertheless, the prevalence of neurological complications of AIDS is increasing. In this study, protein levels of tyrosine hydroxylase (TH) and dopamine transporter (DAT) in the substantia nigra of HIV-infected brains and -seronegative controls were determined by immunoblotting. The immunoreactivity of neuronal specific enolase (NSE) was used to assess cell loss. Although there were no changes in levels of immunoreactive DAT or NSE proteins in HIV brains, levels of immunoreactive TH were significantly reduced, relative to controls. These results suggest that decreases in TH, the rate-limiting enzyme of dopamine synthesis, may be a factor in the neurological manifestations of HIV infection.
This is a preview of subscription content, log in via an institution to check access.
References
Adamson DC, Dawson TM, Zink MC, Clements JE, Dawson VL (1996). Neurovirulent simian immunodeficiency virus infection induces neuronal, endothelial, and glial apoptosis. Mol Med 2: 417–428.
Aksenov MY, Hasselrot U, Wu G, Nath A, Anderson C, Mactutus CF, Booze RM (2003). Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res 987: 1–9.
Arendt G (2005). Neurological manifestations of HIV-infection in the era of highly active antiretroviral therapy (HAART). Fortschr Neurol Psychiatr 73: 577–586.
Berger JR, Arendt G (2000). HIV dementia: the role of the basal ganglia and dopaminergic systems. Psychopharmacol 14: 214–221.
Blanchard-Fillion B, Souza JM, Friel T, Jiang GC, Vrana K, Sharov V, et al. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J Biol Chem 279: 46017–46023.
Blennow K, Wallin A, Ekman R (1994). Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders? J Neural Transm Park Dis Dement Sect 8: 183–91.
Boven LA, Gomes L, Hery C, Gray F, Verhoef J, Portegies P, et al. (1999). Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J Immunol 162: 4319–4327.
Butterfield DA, Stadtman ER (1997). Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2: 161–191.
Dewhurst S, Gelbard HA, Fine SM (1996). Neuropathogenesis of AIDS. Mol Med Today 2: 16–23.
Ding M, Haglid KG, Hamberger A (2000). Quantitative immunochemistry on neuronal loss, reactive gliosis and BBB damage in cortex/striatum and hippocampus/amygdale after systemic kainic acid administration. Neurochem Int 36: 313–318.
Epstein LG (1998). HIV neuropathogenesis and therapeutic strategies. Acta Paediatr Jpn 40: 107–111.
Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, et al. (2000). Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J NeuroVirol 6: 145–155.
Itoh K, Mehraein P, Weis S. (2000). Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (Berl) 99: 376–384.
Jones MV, Bell JE, Nath A (2000). Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 14: 2709–2713.
Koutsiliery E, Sopper S, Scheller C, ter Meulen V, Riederer P (2002). Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 109: 399–410.
Kumer SC, Vrana KE (1996). Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67: 443–462.
Li L-B, Chen N, Ramamoorthy S, Chi L, Cui X-N, Wang LC, et al. (2004). The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 279: 21012–21020.
Manji H, Miller R (2004). Neurology of HIV infection. J Neurol Neurosurg Psychiatry 75: 29–35.
Mash DC, Pablo J, Ouyang Q, Hearn WL, Izenwasser S (2002). Dopamine transport function is elevated in cocaine users. J Neurochem 81: 292–300.
Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, et al. (1997). Immunochemical analysis of dopamine transporter protein in Parkinson’s disease. Ann Neurology 41: 530–539.
Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, et al. (2000). Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14: 222–227.
Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, et al. (2002). Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31: S62-S69.
Navia BA, Cho ES, Petito CK, Price RW (1986). The AIDS dementia complex. II. Neuropathology. Ann Neurol 19: 525–535.
Reyes MG, Faraldi F, Senseng CS, Flowers C. Fariello R (1991). Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol (Berl) 82: 39–44.
Saito Y, Sharer LR, Epstein LG, Michaels J, Mintz M, Louder M, et al. (1994). Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44: 474–481.
Wallace DR, Dodson S, Nath A, Booze RM (2005). Estrogen attenuates gp120- and tat(1–72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59: 51–60.
Wang J-G, Chang L, Volkow N, Telang F, Logan J, Ernst T, et al. (2004). Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452–2458.
Zauli G, Secchierro P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, et al. (2000). HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275: 4159–4165.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by DA013137 and DA014407 (RMB) HD043680 (CFM) and the National Disease Research Interchange.
Rights and permissions
About this article
Cite this article
Silvers, J.M., Aksenov, M.Y., Aksenova, M.V. et al. Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. Journal of NeuroVirology 12, 140–145 (2006). https://doi.org/10.1080/13550280600724319
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280600724319